What It Takes to Launch in 2025: MFN, MFP, IRA, and the New Rules of the Road
Pharmaceutical product launches are evolving—success now requires a clear understanding of emerging regulations and policy dynamics. In this on-demand webinar, industry experts break down how Most Favored Nation (MFN) policies, evolving Maximum Fair Price (MFP) guidelines, and the Inflation Reduction Act (IRA) are reshaping the drug launch landscape.
In this session, you will learn:
-
The latest developments on MFN and MFP and how they impact launch timelines and pricing strategy
-
Key IRA provisions already affecting revenue models and market access
-
Actionable steps to strengthen launch readiness under today’s regulatory pressures
-
Proven strategies for navigating compliance challenges before, during, and after launch
Ready to build a launch strategy fit for 2025’s new road rules?
Download the full webinar to gain timely insights and prepare your team for a successful product introduction.
Thank You for Watching!
Launching a pharmaceutical product in today’s environment means facing unprecedented regulatory complexity. With Most Favored Nation (MFN) policies on the horizon, Maximum Fair Price (MFP) requirements emerging, and Inflation Reduction Act (IRA) provisions already transforming revenue models, the margin for error has never been smaller. One strategic misstep can lead to delays, pricing challenges, and lost market opportunities.
If you have any questions about the webinar or require expert guidance on navigating the new regulatory landscape, please contact us at info@rldatixlifesciences.com to connect with one of our industry professionals. Our team is dedicated to helping life sciences organizations optimize their launch strategies and maintain compliance, regardless of how rapidly the rules of the road change.